2008   Print Screen
 
 

QuantRx® Announces FluoroPharma, Inc. to Report Preclinical Data on Alzheimer’s Disease and Prostate Cancer PET Imaging Agents

DOYLESTOWN, PA – September 9, 2008 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, broadcasts that QuantRx’s FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will report on two preclinical studies demonstrating the potential of novel Positron Emission Tomography (PET) molecular imaging agents for detection of Alzheimer’s disease (AD) and prostate cancer at the World Molecular Imaging Congress, in Nice, France on September 10-13, 2008.

The first study, “Synthesis And Biodistribution Of 2-(2-[18f]Fluoroethyl)-8-Methyl-2,8-Diazaspiro[4,5]Decane-1,3,-Dione ([18f]Fluoro-RS-86), A Muscarinic Acetylcholine Receptor Agonist” describes the synthesis, tissue distribution and pharmacokinetic profile of 18F labeled RS-86, a known M1 muscarinic receptor agonist. FluoroPharma has developed a novel biomarker approach for evaluating the progression of Alzheimer’s disease based on targeting acetylcholine receptors’ activity in the brain. As explained by Dr. Elmaleh, “Acetylcholine receptors have become a potential therapeutic target for improving cognitive function, since the receptors’ function in patients with AD is impaired due to accumulation of amyloid plaque. In conjunction with PET imaging, FluoroPharma’s compound may be a novel approach to the diagnosis of AD and other neurological diseases and the evaluation of new therapeutics.”

The second study, “Accumulation Of F-18 Labeled Modified Fatty Acid (CardioPET) In Prostate Tumor Cells: A Potential Sensitive Pet Tracer For Prostate Imaging” explores the potential of CardioPET, a fatty acid analog, to detect prostate cancer. CardioPET concentrates in significant amounts in human prostate tumor cells and shows potential as a highly sensitive agent for detecting prostate cancer. Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States.

“These new molecular imaging approaches complement FluoroPharma’s existing cardiovascular clinical programs and warrant further evaluation”, says Dr. Kundakovic, FluoroPharma’s President.  “We look forward to expanding our discovery and development of molecular imaging pharmaceuticals for PET to meet the growing needs in neurology and oncology.”

About QuantRx Biomedical (www.quantrx.com)

QuantRx Biomedical Corporation (OTCBB:QTXB) is a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by healthcare professionals and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care.

The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than three dozen patents, patents pending and licensed patents, includes: (1) RapidSense® point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets; (2) genome-based diagnostic chips for the laboratory and healthcare professional markets; (3) molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment; and (4) PAD technology for diagnosis and treatment of women's health concerns and other medical needs.

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries.

 

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company’s need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

 

CONTACTS:

Adam Lowensteiner (Investors)

Alisa Steinberg (Media)                                                                                                   

Wolfe Axelrod Weinberger Associates, LLC                                                               

212-370-4500                                                                                                                      

adam@wolfeaxelrod.com

alisa@wolfeaxelrod.com

 

 

 


 

 

 


© Copyright 2007 - QuantRx® Biomedical Corporation